您现在位置：健康网-医药产业 >> 研究报告 >> English reports >> English reports >> 浏览医药行业研究报告

Antasthmatic Market BreakDown Briefing

健康网讯：

Publisher: Orient Health Electronic Commercial(Beijing)co.,Ltd
Published: 
Format:  Hardcopy and Adobe PDF 
Price:  US$2,100 
Contact: Mr. Bian chenghua   Ms. Wu huifang
Tel.: 86-10-68012929-2105/2101             Fax:  86-10-68052505
E-mail: bianch@healthoo.com   wuhf@healthoo.com 



Table of contents
Summary
1.	Epidemiology of asthma and market scales
  1.1	Morbidity rate
  1.2	Market scales
2.	Categories, mechanism of action and application of antasthmatic
  2.1	Categories of antasthmatic
  2.2	Mechanism of action and application of antasthmatic
3.	Market scales and growth trend of antasthmatic
  3.1	Drugs shares in hospital and growth rate from 2002 to 2005
  3.2	Drugs shares of competitive enterprises in hospital from 2002 to 
2005
  3.3	Rank of antasthmatic from 2002 to 2005
4.	Typical antasthmatic market breakdown
  4.1	β receptor agonists
      Salbutamol
      Terbutaline
      Procaterol
      Salmeterol
      Formoterol
      Bambuterol
  4.2	Phosphodiesterase inhibitors
      Theopylline
      Doxofylline
      Hyphylline
      Aminophylline
  4.3	Anticholinergic agents
      Ipratropium Bromide
  4.4	Leukotriene receptor antagonist
      Montelukast
      Zafirlukast
  4.5	Glucocorticosteroid
      Budesonide
      Beclometasone
      Fluticasone propionate
  4.6	Compound preparation
      Asmeton “strong” capsules
      Salmeterol Xinafoate and Fluticasone Propionate
5.	Market scales and growth rate of key breeds
  5.1	Market scales and growth rate of Budesonide
  5.2	Market scales and growth rate of Salmeterol Xinafoate and Flutica
sone Propionate
  5.3	Market scales and growth rate of Formoterol
  5.4	Market scales and growth rate of Montelukast
6.	The appraisal of antasthmatic API demands in China
7.	Development of new products
  7.1	Application institution of new drugs
  7.2	Introduction of developing new drugs which is not yet or about to
 China
Appendix 1 Breeds of Basic Medical Insurance Medicine List in 2004
Appendix 2 Products of antasthmatic drugs approved by SFDA

Tables and figures
Table 1 Categories of antasthmatic drugs
Table 2 Growth rate of sales values of Antasthmatic drugs from 2002 to 
2005
Table 3 Antasthmatic drugs shares of enterprises from 2002 to 2005
Table 4 Top 20 best-selling Antiasthmatic drugs in 2005
Table 5 Top 20 best-selling Antiasthmatic drugs in 2004
Table 6 Top 20 best-selling Antiasthmatic drugs in 2003
Table 7 Top 20 best-selling Antiasthmatic drugs in 2002
Table 8 Top 10 Antiasthmatic drugs ranked by average annual growth from
 2002 to 2005
Table 9 Top 20 leading enterprises for Salbutamol in 2005
Table 10 Top 20 leading enterprises for Terbutaline in 2005
Table 11 Top 20 leading enterprises for Procaterol in 2005
Table 12 Top 20 leading enterprises for Salmeterol in 2005
Table 13 Top 20 leading enterprises for Formoterol in 2005
Table 14 Top 20 leading enterprises for Bambuterol in 2005
Table 15 Top 20 leading enterprises for Theophylline in 2005
Table 16 Top 20 leading enterprises for Doxofylline in 2005
Table 17 Top 20 leading enterprises for Diprophylline in 2005
Table 18 Top 20 leading enterprises for Aminophylline in 2005
Table 19 Top 20 leading enterprises for Ipratropium Bromide in 2005
Table 20 Top 20 leading enterprises for Montelukast in 2005
Table 21 Top 20 leading enterprises for Zafirlukast in 2005
Table 22 Top 20 leading enterprises for Budesonide in 2005
Table 23 Top 20 leading enterprises for Beclometasone in 2005
Table 24 Top 20 leading enterprises for Fluticasone Propionate in 2005
Table 25 Top 20 leading enterprises for Asmeton “strong” Capsules in 
2005
Table 26 Top 20 leading enterprises for Salmeterol Xinafoate and
 Fluticasone Propionate in 2005
Table 27 Sales values and growth rate of Budesonide of different
 enterprises from 2002 to 2005
Table 28 Sales values and growth rate of Salmeterol Xinafoate and
 Fluticasone Propionate of different enterprises from 2002 to 2005
Table 29 Sales values and growth rate of Formoterol of different
 enterprises from 2002 to 2005
Table 30 Sales values and growth rate of Montelukast of different
 enterprises from 2002 to 2005
Table 31 New drugs of Budesonide approved by SFDA from 2003 to 2006
Table 32 New drugs of Formoterol approved by SFDA from 2003 to 2006
Table 33 Antiasthmatic drugs of Basic Medical Insurance Medicine List
 in 2004

Figure 1 Sales values of Antiasthmatic drugs from 2002 to 2005
Figure 2 Market shares of major enterprises of Antiasthmatic drugs in
 2005
Figure 3 Sales values and growth rate of Budesonide from 2002 to 2005
Figure 4 Sales values of Budesonide of enterprises from 2002 to 2005
Figure 5 Sales values and growth rate of Salmeterol Xinafoate and
 Fluticasone Propionate from 2002 to 2005
Figure 6 Sales values and growth rate of Formoterol from 2002 to 2005
Figure 7 Sales values of Formoterol of enterprises from 2002 to 2005
Figure 8 Sales values and growth rate of Montelukast from 2002 to 2005
Figure 9 Sales values of Montelukast of enterprises from 2002 to 2005